Introduction
Dihydropteridine reductase (DHPR: E.C. 1.6.99.7) is an essential enzyme in the hydroxylating system of the aromatic amino acids and catalyses the regeneration of tetrahydrobiopterin (BH 4 ), the natural cofactor of phenylalanine, tyrosine and tryptophan hydroxylases.
DHPR deficiency has been the first defect des-..:ribed (1) and represents the second most common defect among BH4 deficiencies, covering about one third of all forms (2) .
The cDNA encoding DHPR has been cloned in 1987 (3, 4) and is about 1.2 Kb long. The gene :1as been assigned to the short arm of chromosome -l-, in the region 15 .3. It encodes fc)r a protein of 244 amino acid, active as a homodimer.
So far, sixteen mutations have been described:
mutations are uniformly scattered throughout the coding region (5-9); two further mutations have been identified in the donor splice sites of introns 3 and 4, respectively (8) . The majority of mutations are missense mutations, with only two resulting in premature termination of the peptide chain. A single insertion of one amino acid (5) and a frameshift due to one base deletion, which also aftects splicing (9) , have also been describcd. Most mutations have been found in single § Author to whom correspondence should he 'lddressed .
chromosomes. Only three of them have been identified more than oncc. IVS 4ntl has been found in two patients from United States ( 8, Dianzani I et aI., manuscript in preparation). The others, G23D and H158Y, have been identified in Italian patients (6, 7) .
We report here the distribution of the DHPR mutations in the Italian population. Moreover, since DHPR deficiency is a heterogeneous disease at clinical level, we . attempted to evaluate genotype/ phenotype correlation in a subset of completely characterized patients.
Materials and Methods

Patients
Nine unrelated Italian patients with DHPR de· ficiency were included in this study . ~\'loreo\'er, we considered a patient from Malta, ",hose clinical status and genotype were reported in previous studies (10, 6) .
Hyperphenylalaninemia was detected at neo· natal mass screening or later and a definite diagnosis of DHPR deficiency \\"as obtained lw measurement of urinar; pterins and enzyme activity on dried blood spot. types, some clinical and biochemical parameters were evaluated, when available: pretreatment blood phenylalanine concentration, neurotransmitter metabolites concentrations in cerebrospinal fluid (CSF), CSF pterin levels, urinary pterin excretion, response to oral BH4 loading test (7.5 or 20 mg/kg body weight BH 4 ), response to the combined phenylalanine (100 mg/ kg body weight) and BH4 (20 mg/ kg body weight) oral loading (11), DHPR activity in erythrocytes and/or in fibroblasts, response to treatment (12) .
DNA analysis
Genomic DNA was extracted from peripheral blood leucocytes, using the phenol-chloroform method. G23D and H158Y mutations were searched for in all patients . PCR amplifications of genomic DNA were performed by using appropriate primers. In particular, to detect G23D PCR was performed with primers 5'-CCAG-TTGCGGGCCCGAAAAG-3' and 5' -GCGTGG-ATCCGCGGCGGCTGCA-3'. The amplified product was then incubated at 37°C with the specific endonuclease Hinf I. When a G-> A change occurs at codon 23, a Hinf I restriction site is created in the 106 bp amplified product, yielding two fragments of 68 and 38 bp. To detect H158Y, a PCR was performed with primers 5'-AGTGG-TCACTGAGCCATCT-3' and 5'-ACGGGAAC-CCCAAGCACTT -3' . The amplified product was then incubated at 3TC with the specific endonuclease Hph I. When a C-> T change occurs at codon 158, a Hph I restriction site is abolished in the 166 bp amplified product, yielding a fragment of 166 bp, instead of two fragments of 104 and 62 bp.
Results
Molecular characterization
The molecular characterization of four patients was reported previously (6,7): two patients were Sanctis et at.: Mutations in DHPR deficiency homozygous for G23D, one was homozygous for H158Y and the last patient was a compound heterozygous for G23D and a new identified mutation, YlS0C. This mutation was identified in a larger analysis of the DHPR coding sequence ( Dianzani I. et al, manuscript in preparation). By enzyme digestion a further patient was found homozygote for G23D and another homozygote for H158Y.
Three remaining patients, who did not carry either G23D or H158Y, will be subjected to an extensive exon-screening study to identifY the causal mutations. Geographic origin of the characterized chromosomes could be ascertained: G23D was found in one patient from Sicily, two from Apulia, and in one from Malta (in total 7 chromosomes); H158Y was found in two patients from Sicily (4 chromosomes in total) . We could not establish the Italian origin of the new identified mutation, Y150C, because paternity in this patient has not been confirmed.
Phenotype classification
In Table 1 the clinical aspects of each patients are correlated to the responsible mutations. Since DHPR deficiency is very heterogeneous clinically, we evaluated all available clinical and biochemical parameters to attempt a phenotype classification. A fully definition of phenotype, however, is hampered by difterences in procedures employed for screening and diagnosis, as well as for treatment. Moreover, the response to the BH4 oral load and to the combined phenylalanine + BH4 oral load could not be compared, because of lack standardization of these tests.
Thus, patients were classified into three phenotypes, severe, intermediate, and mild, on the basis of the need for complete or partial or none treatment, respectively. Five patients with a severe phenotype (needing a complete therapy with neurotrasmitter precursors and BH 4 ) lacked DHPR activity either in red blood cells or in fibroblasts and harboured mutations G23D and H158Y in Table 1 . Genotype/phenotype correlation in DHPR deficiency in Italy . The single patient with an intermediate phenotype (needing BH4 monotherapy only) is a compound heterozygote for G23D and Y150C.
Discussion
In this study we attempted to identity the molecular basis of DHPR deficiency in Italy. So far three mutations have been identified in Italian patients: two of them, G23D and H158Y, are associated to a severe phenotype. G23D affects the binding site for NADH, whereas H158Y causes disruption of the overall protein structure. Both mutations deeply inhibit the enzymatic activity in in vitro expression studies (6, 13) . It is noteworthy that the single patient with an intermediate phenotype is a compound heterozygote for G23D and Y150C. Thus, the milder phenotype showed by this patient is probably due to a less severe functional damage induced by the concurrent Y150C mutation. Y150C affects a tyrosine considered to be involved in the pterin binding site, thus essential for the reduction process ( 14) . Moreover, this tyrosine is part of a consensus TyrXXXLys. This sequence is highly conserved among the class of short chain dehydrogenases, which includes DHPR (15) .
Two patients homozygous for G 151 Sand F212C mutations, previously descrihed by Rial! ( 16), could be considered to have a mild form, by our classification. They did not require treatment at all or needed only BH4 treatment. They did not show enzymatic activity in red blood cells, but had a residual activity in fibroblasts, of 4 and 10%, respectively. These two mutant enzymes have not been expressed in in vitro system. G151S mutation involves a conservative substitution (Gly to Ser), that might explain the mild disease state in this patient. In conclusion, two mutations, G23D and H158Y, account together for 55% of DHPR deficient patients in Italy. It is interesting to note that a cluster of DHPR deficient patients had been identified in Southern Italy and the same distribution had been found also for PTPS deficiency (17) . Either heterozygote advantage or genetic drift could be hypothesized to explain the clustering of BH4 defects in Italy, but neither of these mechanisms has been demonstrated so far.
Our data sugg~st that a small number of mutations accounts for most cases of DHPR deficiency in Italy. Accordingly, clinical phenotype results more homogeneous as compared to other 105 populations .
